Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020
Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2
Abbott's FreeStyle Libre 2 CGM picks up Medicare coverage
2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes
Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards
2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes
FreeStyle Libre 2 System (CGM)
Abbott® Freestyle Libre 2 Sensor - Continuous Glucose Monitoring Device (CGM) - Advanced Diabetes Supply®
Diabetes Technology Meeting 2020 - Trisha Shang, Jennifer Y. Zhang, B. Wayne Bequette, Jennifer K. Raymond, Gerard Coté, Jennifer L. Sherr, Jessica Castle, John Pickup, Yarmela Pavlovic, Juan Espinoza, Laurel H. Messer
Freestyle Libre 2 - Continuous Glucose Monitoring System
FreeStyle Libre 2 Continuous Glucose Monitor
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review - Pemberton - 2023 - Diabetes, Obesity and Metabolism - Wiley Online Library
Abbott, Medtronic go head-to-head at ADA conference - Page 2 of 9 - Medical Design and Outsourcing
Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project
2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes
Abbott® Freestyle Libre 2 Sensor - Continuous Glucose Monitoring Device (CGM) - Advanced Diabetes Supply®
Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project
